These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 7292540)
1. 5alpha-reduction of an anti-androgen TSAA-291, 16beta-ethyl-17beta-hydroxy-4-estren-3-one, by nuclear 5alpha-reductase in rat prostates. Sudo K; Yoshida K; Akinaga Y; Nakayama R Steroids; 1981 Jul; 38(1):55-71. PubMed ID: 7292540 [TBL] [Abstract][Full Text] [Related]
2. Anti-androgen TSAA-291. V. Effects of the anti-androgen TSAA-291 on the androgen-receptor complex formation from [3H]testosterone in rat ventral prostates. Sudo K; Yoshida K; Kimura Y; Nakayama R Acta Endocrinol Suppl (Copenh); 1979; 229():67-81. PubMed ID: 294108 [TBL] [Abstract][Full Text] [Related]
3. Anti-androgen TSAA-291. VI. Effects of the anti-androgen TSAA-291 and its related compounds on the in vitro formation of 5 alpha-DHT-receptor complex in the cytosol of rat ventral prostates. Sudo K; Yoshida K; Nakayama R Acta Endocrinol Suppl (Copenh); 1979; 229():82-99. PubMed ID: 294109 [TBL] [Abstract][Full Text] [Related]
4. Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives. Nakayama R; Masuoka M; Masaki T; Shimamoto K Acta Endocrinol Suppl (Copenh); 1979; 229():2-23. PubMed ID: 93380 [TBL] [Abstract][Full Text] [Related]
5. Specific interaction of radioactive anti-androgen TSAA-291 with androgen receptor in rat prostates. Sudo K; Yoshida K; Nakayama R Acta Endocrinol (Copenh); 1982 Jul; 100(3):473-80. PubMed ID: 6214136 [TBL] [Abstract][Full Text] [Related]
6. Anti-androgen TSAA-291. VII. On the mechanism of anti-androgenic action of 16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one (TSAA-291). Nakayama R; Masuoka M; Hiraga K; Miki T Acta Endocrinol Suppl (Copenh); 1979; 229():100-7. PubMed ID: 294104 [TBL] [Abstract][Full Text] [Related]
7. Anti-androgen TSAA-291. III. Hormonal spectra of anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives. Masuoka M; Masaki T; Yamazaki I; Hori T; Nakayama R Acta Endocrinol Suppl (Copenh); 1979; 229():36-52. PubMed ID: 294106 [TBL] [Abstract][Full Text] [Related]
8. Anti-androgen TSAA-291. II. Manifestation of the anti-androgenic action of a steroid ester TSAA-330 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one caproate) and elucidation of its long-lasting mechanism using a simple steroid determination technique. Masuoka M; Shikata M; Fuziwara R; Nakayama R Acta Endocrinol Suppl (Copenh); 1979; 229():24-35. PubMed ID: 294105 [TBL] [Abstract][Full Text] [Related]
9. 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency. Lemus AE; Enríquez J; García GA; Grillasca I; Pérez-Palacios G J Steroid Biochem Mol Biol; 1997 Jan; 60(1-2):121-9. PubMed ID: 9182866 [TBL] [Abstract][Full Text] [Related]
10. Disposition and metabolism of 16 beta-ethyl-17 beta-hydroxy-4-estern-3-one (TSAA-291), a new antiandrogen, in rats. Tanayama S; Yoshida K; Kondo T; Kanai Y Steroids; 1979 Jan; 33(1):65-83. PubMed ID: 452062 [TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors. Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453 [TBL] [Abstract][Full Text] [Related]
12. The antigonadotropic action of testosterone but not 7alpha-methyl-19-nortestosterone is attenuated through the 5alpha-reductase pathway in the castrated male rat pituitary gland. Bandivdekar AH; Karp R; Sundaram K; Kumar N J Androl; 2000; 21(2):268-75. PubMed ID: 10714822 [TBL] [Abstract][Full Text] [Related]
13. Anti-androgen TSAA-291. IV. Effects of the anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) on the secretion of gonadotrophins. Sudo K; Yamazaki I; Masuoka M; Nakayama R Acta Endocrinol Suppl (Copenh); 1979; 229():53-66. PubMed ID: 294107 [TBL] [Abstract][Full Text] [Related]
14. Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile. Hikichi Y; Yamaoka M; Kusaka M; Hara T Eur J Pharmacol; 2015 Oct; 765():322-31. PubMed ID: 26335395 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunoassay for serum levels of an anti-androgen TSAA-291 (Oxendolone) in rats. Sudo K; Masuoka M; Hiraga K; Yoshida K; Nakayama R J Pharmacobiodyn; 1984 Jun; 7(6):378-84. PubMed ID: 6481613 [TBL] [Abstract][Full Text] [Related]
16. Effect of 16 beta-ethyl-17 beta-hydroxy-4-estren-3-one (TSAA-291) on the binding of promegestone (R5020) and methyltrienolone (R1881) to hyperplastic and neoplastic human prostate. Bashirelahi N; Ganesan S; Ekiko DB; Young JD; Shida K; Yamanaka H; Takahashi E J Steroid Biochem; 1986 Sep; 25(3):367-74. PubMed ID: 2430141 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613 [TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750 [TBL] [Abstract][Full Text] [Related]
19. Comparison between the binding of 19-nortestosterone, 5alpha-dihydrotestosterone and testosterone in rat prostate and bulbocavernosus/levator ani muscle. Krieg M; Dennis M; Voigt KD J Endocrinol; 1976 Sep; 70(3):379-87. PubMed ID: 978099 [TBL] [Abstract][Full Text] [Related]
20. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]